• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿液中草酸钙结晶风险的测量。

Measurement of the risk of calcium oxalate crystallization in urine.

作者信息

Tiselius H G

出版信息

Urol Res. 1985;13(6):297-300. doi: 10.1007/BF00262660.

DOI:10.1007/BF00262660
PMID:4095829
Abstract

The risk of calcium crystallization (CaOx-CR) in urine was analyzed by means of crystal counting following standardized addition of oxalate. CaOx-CR was determined in 24 h urine samples from 21 stone formers and 26 normal subjects following dilution of urine to a creatinine concentration of 5 mumol per ml. The mean (+/- SD) CaOx-CR was in stone formers 1.42 +/- 0.57 and in normal subjects 1.29 +/- 0.40. CaOx-CR was also analyzed in 16 fresh urine samples diluted to 80 per cent of the original concentration whereby values between 0.36 and 3.6 were recorded. There was a good correlation between CaOx-CR and estimates of the ion-activity product of CaOx, both in urine diluted to 5 mumol of creatinine per ml and in 80 per cent diluted urine. It ist suggested that the method described is of value for evaluation and follow up of patients with CaOx urolithiasis.

摘要

通过在草酸盐标准化添加后进行晶体计数来分析尿液中草酸钙结晶(CaOx-CR)的风险。在将21名结石形成者和26名正常受试者的24小时尿液样本稀释至肌酐浓度为每毫升5微摩尔后,测定CaOx-CR。结石形成者的平均(±标准差)CaOx-CR为1.42±0.57,正常受试者为1.29±0.40。还对16份稀释至原始浓度80%的新鲜尿液样本进行了CaOx-CR分析,记录的值在0.36至3.6之间。在稀释至每毫升肌酐5微摩尔的尿液以及80%稀释尿液中,CaOx-CR与草酸钙离子活性产物的估计值之间存在良好的相关性。建议所描述的方法对于草酸钙尿路结石患者的评估和随访具有价值。

相似文献

1
Measurement of the risk of calcium oxalate crystallization in urine.尿液中草酸钙结晶风险的测量。
Urol Res. 1985;13(6):297-300. doi: 10.1007/BF00262660.
2
Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.正常人及特发性草酸钙结石患者中过饱和度与草酸钙结晶的关系。
Kidney Int. 1999 Mar;55(3):1041-50. doi: 10.1046/j.1523-1755.1999.0550031041.x.
3
Inhibition of calcium oxalate crystallization in urine.尿液中草酸钙结晶的抑制作用。
Urol Res. 1987;15(2):83-6. doi: 10.1007/BF00260938.
4
Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens.基于即时和24小时尿液样本的草酸钙结石病的尿饱和度及危险因素
Front Biosci. 2003 Sep 1;8:a167-76. doi: 10.2741/1139.
5
The effect of pH on the risk of calcium oxalate crystallization in urine.pH对尿液中草酸钙结晶风险的影响。
Eur Urol. 1986;12(1):59-61. doi: 10.1159/000472578.
6
Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers.对正常受试者和草酸钙结石形成者经标准化体积调整的12小时夜间尿液中的尿液成分及钙盐结晶特性进行评估。
Urol Res. 1997;25(5):365-72. doi: 10.1007/BF01294667.
7
Aspects on estimation of the risk of calcium oxalate crystallization in urine.尿液中草酸钙结晶风险评估的相关方面。
Urol Int. 1991;47(4):255-9. doi: 10.1159/000282232.
8
Effects of urinary macromolecules on the nucleation of calcium oxalate in idiopathic stone formers and healthy controls.尿大分子对特发性结石形成者和健康对照者草酸钙成核的影响。
Clin Chim Acta. 1995 Jul 31;239(1):1-11. doi: 10.1016/0009-8981(95)06092-r.
9
Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas.尿样草酸钙结晶风险的测定:与其他风险公式相比的波恩风险指数
J Urol. 2004 Jul;172(1):355-9. doi: 10.1097/01.ju.0000123822.20291.4d.
10
An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.一种用于复发性草酸钙结石病患者常规生化评估的改进方法。
Clin Chim Acta. 1982 Jul 15;122(3):409-18. doi: 10.1016/0009-8981(82)90145-0.

引用本文的文献

1
Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?鉴于磷酸钙在病因学上的重要性,我们是否应该修改草酸钙结石病患者的风险评估原则和复发预防治疗方法?
Urolithiasis. 2015 Jan;43 Suppl 1:47-57. doi: 10.1007/s00240-014-0698-4. Epub 2014 Aug 3.
2
Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers.对正常受试者和草酸钙结石形成者经标准化体积调整的12小时夜间尿液中的尿液成分及钙盐结晶特性进行评估。
Urol Res. 1997;25(5):365-72. doi: 10.1007/BF01294667.
3

本文引用的文献

1
Evaluation of a routine method for determination of calcium oxalate crystal growth inhibition in diluted urine samples.评估一种用于测定稀释尿液样本中草酸钙晶体生长抑制的常规方法。
Clin Chem. 1981 Apr;27(4):565-8.
2
Biochemical evaluation of patients with urolithiasis.尿路结石患者的生化评估。
Eur Urol. 1981;7(1):31-4. doi: 10.1159/000473168.
3
Independent assessment of the growth and aggregation of calcium oxalate crystals using the Coulter counter.使用库尔特计数器对草酸钙晶体的生长和聚集进行独立评估。
Intratubular crystallization events.
肾小管内结晶事件。
World J Urol. 1997;15(4):219-28. doi: 10.1007/BF01367659.
4
Risk formulas in calcium oxalate urolithiasis.草酸钙尿路结石的风险公式。
World J Urol. 1997;15(3):176-85. doi: 10.1007/BF02201855.
5
Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine?在高浓度尿液中,柠檬酸盐是草酸钙晶体生长的抑制剂吗?
Urol Res. 1996;24(2):67-71. doi: 10.1007/BF00431081.
6
Measurement of the risk of calcium phosphate crystallization in urine.
Urol Res. 1987;15(2):79-81. doi: 10.1007/BF00260937.
7
Studies of urinary calcium oxalate crystallization in clinical research.临床研究中草酸钙尿结晶的研究。
Urol Res. 1989;17(3):143-4.
8
Urolithiasis--historical, comparative and pathophysiological aspects: a review.尿石症——历史、比较及病理生理学方面:综述
J R Soc Med. 1989 Nov;82(11):669-72. doi: 10.1177/014107688908201112.
9
Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate.不同剂量碱性柠檬酸盐对尿液成分及草酸钙结晶的影响。
Urol Res. 1990;18(1):13-6. doi: 10.1007/BF00294574.
10
Clinical investigations.临床研究。
Urol Res. 1990;18 Suppl 1:S31-5. doi: 10.1007/BF00301525.
Invest Urol. 1981 Mar;18(5):401-5.
4
Determination of urinary oxalate by reversed-phase ion-pair "high-performance" liquid chromatography.反相离子对“高效”液相色谱法测定尿草酸
Clin Chem. 1982 Nov;28(11):2272-4.
5
An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.一种用于复发性草酸钙结石病患者常规生化评估的改进方法。
Clin Chim Acta. 1982 Jul 15;122(3):409-18. doi: 10.1016/0009-8981(82)90145-0.
6
A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation.一种通过引发沉淀所需草酸盐或钙的增量来评估尿液中草酸钙和透钙磷石结晶倾向的简单技术。
Metabolism. 1983 Sep;32(9):906-10. doi: 10.1016/0026-0495(83)90205-6.
7
New methods to determine the state of saturation of urine and to discriminate between the urine of control subjects and stoneformers.确定尿液饱和度状态以及区分对照受试者和结石形成者尿液的新方法。
Clin Biochem. 1983 Apr;16(2):79-86. doi: 10.1016/s0009-9120(83)90428-9.
8
Variations in urine composition during the day in patients with calcium oxalate stone disease.草酸钙结石病患者白天尿液成分的变化。
J Urol. 1984 Jan;131(1):77-81. doi: 10.1016/s0022-5347(17)50211-6.
9
Supersaturation levels and crystallization rates of calcium oxalate from urines of normal humans and stone formers determined by a 14C-oxalate technique.通过14C-草酸盐技术测定正常人和结石形成者尿液中草酸钙的过饱和水平和结晶速率。
Invest Urol. 1974 Nov;12(3):203-9.
10
Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract.
N Engl J Med. 1976 Jan 29;294(5):249-52. doi: 10.1056/NEJM197601292940504.